Physician profile
Day B Breen
NPI 1508121765
$7,671.57
in general payments reported to CMS, 2019-2025
36 companies · $1,305 in 2025
The $1,305 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $377 · 2021: $249 · 2022: $901 · 2023: $1,042 · 2024: $3,155 · 2025: $1,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Travel and Lodging: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.19 |
| Travel and Lodging | $1,157.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $1,759.31 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Livanova USA, INC. | $1,640.86 | 2019-2024 | Vns Therapy |
| Jazz Pharmaceuticals INC. | $754.95 | 2019-2025 | |
| Neurelis, INC. | $731.17 | 2020-2025 | Valtoco |
| Greenwich Biosciences, INC. | $340.03 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $277.61 | 2019-2022 | |
| Eisai INC. | $264.36 | 2019-2023 | |
| Sk Life Science, INC. | $212.45 | 2023-2025 | |
| Upsher-Smith Laboratories LLC | $174.98 | 2020-2025 | |
| Catalyst Pharmaceuticals, INC. | $139.47 | 2023-2025 | Fycompa |
| Immedica Pharma US, INC. | $136.56 | 2022-2025 | Ztalmy |
| Acadia Pharmaceuticals INC | $131.93 | 2023-2025 | Daybue |
| Abbvie INC. | $128.76 | 2023-2025 | Botox |
| Novartis Pharmaceuticals Corporation | $108.09 | 2019-2025 | |
| Aucta Pharmaceuticals, INC. | $96.52 | 2024-2025 | Motpoly Xr |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $90.77 | 2023-2024 | Aptiom |
| Genentech USA, INC. | $78.37 | 2023 | Evrysdi |
| Azurity Pharmaceuticals, INC. | $77.68 | 2023-2025 | Eprontia, Zonisade, Zonisade |
| Genentech, INC. | $64.74 | 2023 | Evrysdi |
| Otter Pharmaceuticals, LLC | $53.49 | 2025 | Sympazan |
| Alexion Pharmaceuticals, INC. | $44.44 | 2022-2025 | Koselugo |
| Ipsen Biopharmaceuticals, INC | $42.15 | 2019-2025 | Dysport |
| Sarepta Therapeutics, INC. | $30.71 | 2023 | Elevidys |
| Saol Therapeutics INC. | $30.33 | 2019 | |
| Ptc Therapeutics, INC. | $29.12 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.10 | 2021-2022 | |
| Biocodex, INC. | $24.13 | 2023 | Diacomit |
| Novartis Gene Therapies, INC. (Fka Avexis, INC.) | $24.05 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.79 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $23.36 | 2025 | Ajovy |
| Travere Therapeutics, INC. | $22.95 | 2019 | |
| Genzyme Corporation | $18.50 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.94 | 2023 | Lyvispah |
| Medtronic, INC. | $17.86 | 2022 | |
| Mallinckrodt Enterprises LLC | $16.92 | 2019 | |
| Zogenix INC. | $14.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Day Breen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.